zlk.com Open in urlscan Pro
162.215.213.178  Public Scan

Form analysis
4 forms found in the DOM

<form id="pop_up_form_st1" class="sf_form_style form_overlay_style">
  <label for="ipt_first_name" class="primary_color font_w7">First Name</label>
  <input id="ipt_first_name" type="text" placeholder="First Name*" name="FName" autocomplete="off">
  <label for="ipt_last_name" class="primary_color font_w7">Last Name</label>
  <input id="ipt_last_name" type="text" placeholder="Last Name*" name="LName" autocomplete="off">
  <label for="ipt_email" class="primary_color font_w7">Email</label>
  <input id="ipt_email" type="text" placeholder="Email address*" name="Email" autocomplete="off">
  <input id="ipt_name" type="hidden" name="Name">
  <input type="hidden" name="ArriveTime" value="2024-06-07 19:49:13">
  <p class="grey_c4 font_st font_w5 center_align">Levi &amp; Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit. No spam will be sent to your email.</p>
  <div class="btn_sf_style">
    <input type="submit" id="btn_pu_form1" value="Sign Up" disabled="">
  </div>
</form>

<form id="pop_up_form_st2" class="sf_form_style form_overlay_style">
  <label for="ipt_phone" class="primary_color font_w7">Phone</label>
  <input id="ipt_phone" type="text" placeholder="Phone Number*" name="Phone" autocomplete="off">
  <div id="pu_agree_wrapper">
    <div><input type="checkbox" id="pu_ck_agree" name="Agree"></div>
    <label for="pu_ck_agree" class="grey_c4 font_st">By checking this box, you agree to receive text message updates from Levi &amp; Korsinsky. We'll keep you informed on the latest settlement developments and important updates related to settlement
      information. Standard messaging rates may apply. You can opt-out at any time.</label>
  </div>
  <input type="hidden" name="id" value="">
  <div class="btn_sf_style">
    <input type="submit" id="btn_pu_form2_skip" value="Skip">
    <input type="submit" id="btn_pu_form2" value="Submit" disabled="">
  </div>
</form>

GET https://zlk.com/attorneys/

<form action="https://zlk.com/attorneys/" method="get" id="attorney_form">
  <input type="text" name="attorney" id="attr_name_ipt" placeholder="Attorney Name*">
  <p class="warning_msg">Required Field</p>
  <div id="primary_dropdown_wrapper">
    <div id="primary_dropdown">
      <input type="text" id="prac_area_ipt" placeholder="Practice Area" name="practice_area" data-area-name="" readonly="">
      <i class="fa-solid fa-chevron-down"></i>
    </div>
    <div id="dropdown_list">
      <ul>
        <li data-area="practice_area" id="current_dropdown">Practice Area</li>
        <li data-area="corporate_governance">Corporate Governance</li>
        <li data-area="executive_compensation">Executive Compensation</li>
        <li data-area="securities_fraud">Securities Fraud</li>
        <li data-area="mergers__acquisitions">Mergers &amp; Acquisitions</li>
        <li data-area="consumer">Consumer</li>
      </ul>
    </div>
  </div> <button id="btn_attr_search" class="black_c4 bg_color3 right_float" type="submit">Search</button>
</form>

GET https://zlk.com/cases/

<form action="https://zlk.com/cases/" method="get" id="case_form">
  <input type="text" id="company_name_ipt" class="left_float" name="company" placeholder="Company Name">
  <input type="text" id="ticker_ipt" class="left_float" name="symbol" placeholder="Symbol">
  <button id="btn_case_search" class="black_c4 bg_color3 left_float" type="submit">Find Case</button>
</form>

Text Content

NEVER MISS A POTENTIAL RECOVERY AGAIN

SIGN UP FOR CLASS
ACTION ALERTS

Each year, class action lawsuits generate billions of dollars in settlement
funds, but many shareholders fail to file a claim. Stay in the know regarding
class action lawsuits by signing up for alerts.

First Name Last Name Email

Levi & Korsinsky, LLP does not share your information with others. There is no
cost or obligation for you to submit. No spam will be sent to your email.


Phone

By checking this box, you agree to receive text message updates from Levi &
Korsinsky. We'll keep you informed on the latest settlement developments and
important updates related to settlement information. Standard messaging rates
may apply. You can opt-out at any time.


Cases Settlements Attorneys Firm L&K Insights News
 * Cases
 * Settlements
 * Attorneys
 * Firm
 * L&K Insights
 * News




WE GIVE SHAREHOLDERS A VOICE.

The market fluctuates, but we don’t. We give you straight answers from real
attorneys who have spent decades helping shareholders protect their investments
and recover their losses.




SETTLEMENTS

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

Class Counsel have demonstrated that they are skilled in this area of the law
and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management,
kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec.
Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

I think you’ve done a superb job and I really appreciate the way this case was
handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct.
for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No.
600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290
(S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our
“extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law
and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management,
kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec.
Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

I think you’ve done a superb job and I really appreciate the way this case was
handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct.
for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No.
600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290
(S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our
“extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law
and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management,
kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec.
Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

 * 1
 * 2
 * 3
 * 4
 * 5


WHO WE ARE

We combine specialized securities expertise with an innovative approach to
litigation and an enduring commitment to our clients. We represent individuals,
institutions, and asset managers in some of the largest, most complex securities
cases in the country and never shy away from an uphill battle.

Online casinos that accept a minimum deposit of $10 are a great option for
players who want to try out their luck without risking too much money. These 10
dollar deposit casinos offer a variety of games, including slots, table games,
and live dealer games, as well as various payment options to make depositing and
withdrawing funds easy.

Nos últimos anos, os casinos online tornaram-se extremamente populares, e um
número crescente de jogadores está a optar por fazê-lo a partir do conforto das
suas próprias casas. Um dos métodos de pagamento mais bem aceites pelos casinos
online é o PayPal, uma carteira digital que permite aos utilizadores depositar e
receber dinheiro de forma simples e segura. Os casinos PayPal são
estabelecimentos de jogo online que aceitam PayPal como forma de pagamento.
A popularidade do PayPal como método de pagamento de casino online pode ser
atribuída tanto à sua usabilidade como às suas características de segurança.
Quando utiliza o PayPal para fazer um depósito ou levantamento num casino, não
precisa de dar ao casino acesso aos seus dados financeiros pessoais. Apenas
precisa do seu endereço de e-mail e palavra-passe PayPal para completar a
transacção. Isto reduz significativamente a probabilidade de fraude e roubo de
identidade. Além disso, as transacções PayPal são processadas rapidamente,
permitindo-lhe começar quase imediatamente a jogar os jogos de casino que
escolheu.

Mi is a status company working with securities and innovative approaches with
online casino gamblers. We provide you with an open door to our offices where
online casino players can view a win palace review. Our company, together with
online casinos, works in more than 40 courts throughout the country and is
considered the best company.

O facto de o PayPal ser amplamente reconhecido é um benefício adicional da sua
utilização num casino online pagamento Paypal. Porque o PayPal é um método de
pagamento fiável e bem respeitado, vários casinos online decidiram incluí-lo na
sua lista de métodos de pagamento aprovados. Tem agora opções adicionais para
jogar porque uma variedade de casinos em linha aceita PayPal para depósitos e
levantamentos.
Um casino PayPal é um casino online que aceita PayPal como uma forma de
pagamento. Ao optar por financiar as suas contas em casinos online com PayPal,
os jogadores têm uma opção segura, segura e útil. Dada a sua conveniência,
características de segurança, e aceitação geral, faz sentido que o PayPal se
tenha tornado um dos métodos de pagamento mais frequentemente utilizados para
casinos online. Se procura um método de pagamento fiável e de confiança para as
suas actividades de jogo online, pense em utilizar PayPal num casino que aceite
PayPal.

In the fast-paced world of online casinos, one of the most critical elements to
ensuring that their business is legally compliant is working with the best
lawyers. The legal landscape around online gambling is complex and constantly
evolving, making it essential for online casinos to have legal experts on hand
to help navigate this tricky terrain. In this article, we will explore how
online casinos cooperate with the best lawyers and why this is essential to
their success. Firstly, working with the best lawyers can help online casinos
https://casinosworld.ca/best-payout-online-casinos/ ensure that they are
operating within the confines of the law. Online gambling regulations can vary
significantly from jurisdiction to jurisdiction, and it can be challenging for
online casinos to stay on top of the latest changes. By working with experienced
lawyers who specialize in gambling law, online casinos can be confident that
they are always up to date with the latest legal developments and that their
business is fully compliant.

Ice hockey is one of the most exciting and dynamic sports in the world, and it’s
no surprise that many people enjoy betting on it. However, one group of
professionals that has taken a particular interest in hockey betting is lawyers
and attorneys. In this article, we will explore why hockey betting is popular
among lawyers and attorneys and what they enjoy about this unique form of
gambling. One reason that lawyers and attorneys enjoy hockey betting is that it
requires a deep understanding of the game and its rules. As legal professionals,
they are trained to analyze complex information and make informed decisions
based on that information. This analytical approach is well-suited to sports
betting, where successful bettors must understand the intricacies of the game
and make informed decisions based on those details. Hockey betting provides a
unique challenge that many lawyers and attorneys find appealing. Another reason
that hockey betting
https://thewincolumn.ca/2023/02/11/sports-betting-101-how-to-bet-on-hockey/ is
popular among lawyers and attorneys is that it allows them to stay up to date
with the latest legal developments in the sports world. As legal professionals,
they are always looking for new opportunities to expand their knowledge and
expertise. By betting on hockey, they can stay up to date with the latest
developments in the sport, including any changes to the rules or regulations
that may affect betting odds.




We're here for you


FIND AN ATTORNEY

Required Field

 * Practice Area
 * Corporate Governance
 * Executive Compensation
 * Securities Fraud
 * Mergers & Acquisitions
 * Consumer

Search


Don't hesitate


FIND A CASE

Find Case


UPCOMING DEADLINES

Investors interested in taking an active role in litigation have a limited time
to petition the court for appointment as lead plaintiff. If you are interested
in acting as a lead plaintiff, submit your transactions before the deadline, and
our analysts will calculate your losses. Don't wait till the last minute-
discuss your options today.
View All Deadlines

52

Days Left

ENPH

ENPHASE ENERGY, INC.

Deadline

July 29 2024

Class Period

2/7/23 - 4/25/23

Allegations

According to the complaint, on April 25, 2023, Enphase issued a press release
announcing its first quarter earnings. In pertinent part, defendants announced
revenue in the United States had decreased by approximately 9% attributing it to
macroeconomic conditions. Additionally, defendants put out a weak second quarter
outlook for 2023 where revenue was estimated to be within the range of $700
million to $750 million. Following this news, the price of Enphase’s common
stock declined dramatically. From a closing market price of $220.60 per share on
April 25, 2023, Enphase’s stock price fell to $163.83 per share on April 26,
2023, a decline of nearly 26% in the span of just a single day.

Class Period

2/7/23 - 4/25/23

Deadline

July 29 2024

Learn More

53

Days Left

RIVN

RIVIAN AUTOMOTIVE, INC.

Deadline

July 30 2024

Class Period

8/12/22 - 2/21/24

Allegations

(i) Rivian had overstated demand for its products, as well as its ability to
withstand negative, near-term macroeconomic impacts; (ii) accordingly, Rivian’s
business was experiencing reduced demand and increased customer cancellations as
a result of, inter alia, high interest rates; (iii) as a result, Rivian’s order
bank had significantly deteriorated; (iv) all the foregoing was likely to, and
did, negatively impact the Company’s anticipated earnings and vehicle production
targets for 2024; and (v) as a result, the Company’s public statements were
materially false and misleading at all relevant times.

Class Period

8/12/22 - 2/21/24

Deadline

July 30 2024

Learn More

53

Days Left

HTZ

HERTZ GLOBAL HOLDINGS, INC.

Deadline

July 30 2024

Class Period

4/27/23 - 4/24/24

Allegations

(i) Hertz had downplayed the financial impact of vehicle depreciation, and/or
overstated its ability to track and manage vehicle depreciation; (ii) demand for
Hertz’s EVs was not as strong as Defendants had led investors to believe; (iii)
Hertz had too many vehicles, particularly EVs, in its fleet to remain
profitable; (iv) as a result of all the foregoing, Hertz was likely to incur
significant losses on the disposition of both its ICE vehicles and EVs; (v) all
the foregoing was likely to, and did, have a significant negative impact on
Hertz’s financial results; and (vi) as a result, the Company’s public statements
were materially false and misleading at all relevant times.

Class Period

4/27/23 - 4/24/24

Deadline

July 30 2024

Learn More

59

Days Left

MRNS

MARINUS PHARMACEUTICALS, INC.

Deadline

August 5 2024

Class Period

3/17/21 - 5/7/24

Allegations

(1) defendants understated the risk of failure to meet the early-stopping
criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2)
defendants did not disclose that a possible consequence of failing to meet the
early stopping criteria in the RAISE trial would be that Marinus would stop the
separate Phase 3 RAISE II trial; and (3) as a result, defendants’ statements
about its business, operations, and prospects, were materially false and
misleading and/or lacked a reasonable basis at all times.

Class Period

3/17/21 - 5/7/24

Deadline

August 5 2024

Learn More

4

Days Left

VFS

VINFAST AUTO LTD. F/K/A BLACK SPADE ACQUISITION CO.

Deadline

June 11 2024

Class Period

8/15/23 - 1/17/24

Allegations

(i) VinFast lacked sufficient capital to execute its purported growth strategy;
(ii) VinFast would be unable to meet its 2023 delivery targets; (iii)
accordingly, VinFast had overstated the strength of its business model and
operational capabilities, as well as its post- merger business and/or financial
prospects; and (iv) as a result, the offering documents and defendants’ public
statements throughout the class period were materially false and/or misleading
and failed to state information required to be stated therein.

Class Period

8/15/23 - 1/17/24

Deadline

June 11 2024

Learn More

4

Days Left

QDEL

QUIDELORTHO CORPORATION F/K/A QUIDEL CORPORATION

Deadline

June 11 2024

Class Period

2/18/22 - 4/1/24

Allegations

(a) that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy
chain customers than they could resell to healthcare providers and end
customers; (b) that excess inventories of COVID-19 tests existed throughout the
supply chain; (c) that, as a result of (a)-(b) above, QuidelOrtho’s distributors
and pharmacy chain customers were poised to significantly reduce their COVID-19
test orders; (d) that undisclosed problems created a heightened risk that the
new test called the savanna respiratory viral panel-4 test would experience a
delayed commercial launch in the united states; (e) that, as a result of (a)-(d)
above, defendants lacked a reasonable basis for their positive statements about
QuidelOrtho’s business, financials, and growth trajectory.

Class Period

2/18/22 - 4/1/24

Deadline

June 11 2024

Learn More

10

Days Left

PERI

PERION NETWORK LTD.

Deadline

June 17 2024

Class Period

2/9/21 - 4/5/24

Allegations

(1) Perion’s search advertising business was not a reliable and significant
growth driver and was in fact in decline; (2) Perion’s long-term relationship
with Microsoft and search services agreement would not provide stability for
Perion’s search advertising business; (3) there was an increased risk of
Microsoft acting to unilaterally change its advertising pricing and mechanisms
to the detriment of Perion while the search services agreement was in place; (4)
Perion’s AI technology and Microsoft’s investment in ChatGPT, a form of
generative AI, would not protect or grow Perion’s search advertising revenue;
and (5) based on the foregoing, defendants lacked a reasonable basis for their
positive statements about Perion’s search advertising business and related
financial results, growth, and prospects.

Class Period

2/9/21 - 4/5/24

Deadline

June 17 2024

Learn More

10

Days Left

ASTS

AST SPACEMOBILE, INC.

Deadline

June 17 2024

Class Period

11/14/23 - 4/1/24

Allegations

(1) production of the Company’s five first generation of commercial satellites,
Block 1 BlueBird satellites, had been negatively impacted by two suppliers of
key subsystems; (2) a result, the Company had not substantially completed the
production of the Block 1 BlueBird satellites; (3) as a result, the Company’s
five Block 1 BlueBird satellites were not on track to launch in the first
quarter of 2024; and (4) as a result of the foregoing, defendants’ positive
statements about the Company’s business, operations, and prospects were
materially misleading and/or lacked a reasonable basis.

Class Period

11/14/23 - 4/1/24

Deadline

June 17 2024

Learn More

11

Days Left

SHCR

SHARECARE, INC.

Deadline

June 18 2024

Class Period

5/10/23 - 3/28/24

Allegations

(1) Sharecare lacked adequate internal controls and; (2) as a result,
defendants’ statements about its business, operations, and prospects, were
materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

5/10/23 - 3/28/24

Deadline

June 18 2024

Learn More

14

Days Left

GDRX

GOODRX HOLDINGS, INC.

Deadline

June 21 2024

Class Period

9/23/22 - 11/8/22

Allegations

(1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx
discounts, Kroger was responsible for nearly 25% of GoodRx’s total prescription
transactions revenue (the Company’s primary revenue stream); and (2) Kroger
could unilaterally cease accepting GoodRx discounts, cutting off some or all of
GoodRx’s revenues for purchases at Kroger’s pharmacies; and (3) as a result,
defendants’ representations about the Company’s business, operations, and
prospects were materially false and misleading and/or lacked a reasonable basis.

Class Period

9/23/22 - 11/8/22

Deadline

June 21 2024

Learn More

17

Days Left

LNC

LINCOLN NATIONAL CORPORATION

Deadline

June 24 2024

Class Period

11/4/20 - 11/2/22

Allegations

(1) the Company was experiencing a decline in its variable universal life
insurance business; (2) as a result, the goodwill associated with the life
insurance business was overstated; (3) as a result, the Company’s policy lapse
assumptions were outdated; (4) as a result, the Company’s reserves were
overstated; (5) as a result, the Company’s reported financial results and
financial statements were misstated; and (6) as a result of the foregoing,
defendants’ positive statements about the Company’s business, operations, and
prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/4/20 - 11/2/22

Deadline

June 24 2024

Learn More

17

Days Left

CMP

COMPASS MINERALS INTERNATIONAL, INC.

Deadline

June 24 2024

Class Period

11/29/23 - 3/22/24

Allegations

(1) Compass Minerals overstated the likelihood that it would be awarded a
renewed U.S. Forest Service contract for the use of its proprietary magnesium
chloride-based aerial fire retardants for the 2024 fire season, as a result of
safety issues presented by its fire retardant; (2) Compass Minerals materially
overstated the extent to which testing had confirmed that its fire retardants
were safe; and (3) as a result, defendants’ statements about its business,
operations, and prospects were materially false and misleading and/or lacked a
reasonable basis at all times.

Class Period

11/29/23 - 3/22/24

Deadline

June 24 2024

Learn More

17

Days Left

ADSK

AUTODESK, INC.

Deadline

June 24 2024

Class Period

6/1/23 - 4/16/24

Allegations

(1) Autodesk, Inc. lacked adequate internal controls as a result of issues with
its free cash flow and non-GAAP operating margin practices; and (2) as a result,
defendants’ statements about its business, operations, and prospects were
materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

6/1/23 - 4/16/24

Deadline

June 24 2024

Learn More

18

Days Left

AKRO

AKERO THERAPEUTICS, INC.

Deadline

June 25 2024

Class Period

9/13/22 - 10/9/23

Allegations

(i) approximately 20% of the patients enrolled in the SYMMETRY study, a trial
that purportedly tested efruxifermin ("EFX") in patients with nonalcoholic
steatohepatitis (“NASH”) -induced cirrhosis, had cryptogenic cirrhosis and did
not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients
included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis
due to definitive NASH; (iii) the results from the cryptogenic cirrhosis
patients were to be excluded from the calculation of the NASH resolution
secondary endpoints; (iv) Akero had introduced a confounding factor into the
SYMMETRY study’s design, materially influencing the study’s potential results
and increasing the risks that the study would fail to meet its primary endpoint;
(v) the SYMMETRY study did not align with U.S. Food & Drug Administration
guidance for testing a drug in treating NASH cirrhotics because Akero had not
rule out potential causes of each patient’s cirrhosis other than NASH; and (vi)
consequently, Akero had materially misrepresented the nature of the SYMMETRY
trial, its usefulness in supporting any new drug application, the likelihood
that the SYMMETRY trial would be successful as measured by its primary endpoint,
and the likelihood that EFX would become a commercial treatment for NASH
cirrhotics.

Class Period

9/13/22 - 10/9/23

Deadline

June 25 2024

Learn More

21

Days Left

MBUU

MALIBU BOATS, INC.

Deadline

June 28 2024

Class Period

11/4/22 - 4/11/24

Allegations

(1) Malibu Boats had engaged in an “elaborate scheme to over manufacture and
pump nearly $100 million of its highest priced, highest margin, slow moving boat
inventory into fifteen Tommy’s dealerships”; (2) as a result, the Company
artificially inflated Malibu’s sales performance, market share, and stock value;
(3) the Company was withholding certain incentives and rebates from its dealers;
(4) as a result of the foregoing, the Company faced substantial risk of
litigation from one of its top dealers, Tommy’s; (5) the Company’s CEO departed
due to his role in this scheme; and (6) as a result of the foregoing,
defendants’ positive statements about the Company’s business, operations, and
prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/4/22 - 4/11/24

Deadline

June 28 2024

Learn More

24

Days Left

GL

GLOBE LIFE INC. F/K/A TORCHMARK CORPORATION

Deadline

July 1 2024

Class Period

5/8/19 - 4/10/24

Allegations

According to the complaint, throughout the Class Period, Globe Life reported
consistent premium revenue growth at the Company, led by consistent premium
revenue growth at American Income Life Insurance Company (“AIL”). The Company
also represented that its employees adhered to a code of conduct that expressly
prohibited various forms of misconduct, and which required that all Globe Life
employees comply with relevant laws and regulations, purportedly ensuring that
the Company would maintain a workplace free from violence, threatening behavior,
and illegal drugs. In truth, Globe Life was engaged in wide-spread insurance
fraud, therefore inflating Globe Life’s financial results. In addition, Globe
Life permitted a culture of unchecked sexual harassment, in direct contravention
of the Company’s Code of Conduct. As a result of defendants’ misrepresentations,
shares of Globe Life common stock traded at artificially inflated prices
throughout the Class Period.

Class Period

5/8/19 - 4/10/24

Deadline

July 1 2024

Learn More

24

Days Left

EQIX

EQUINIX, INC.

Deadline

July 1 2024

Class Period

5/3/19 - 3/24/24

Allegations

(1) Equinix manipulated its financials to reduce operational expenses and boost
Adjusted Funds From Operations (“AFFO”); (2) Equinix oversold power capacity and
did not warn of the risks associated with this practice; (3) Equinix lacked
adequate internal controls; and (4) as a result, defendants’ public statements
were materially false and/or misleading at all relevant times.

Class Period

5/3/19 - 3/24/24

Deadline

July 1 2024

Learn More

25

Days Left

INTC

INTEL CORPORATION

Deadline

July 2 2024

Class Period

1/25/24 - 4/25/24

Allegations

(1) the growth of Intel Foundry Services was not indicative of revenue growth
reportable under the Internal segment; (2) the Foundry experienced significant
operating losses in 2023; (3) the Foundry experienced a decline in product
profit driven by lower internal revenue; (4) as a result the Foundry model would
not be a strong tailwind to the Company’s IFS strategy; and (5) as a result of
the foregoing, defendants’ positive statements about the Company’s business,
operations, and prospects were materially misleading and/or lacked a reasonable
basis.

Class Period

1/25/24 - 4/25/24

Deadline

July 2 2024

Learn More

28

Days Left

AXTI

AXT, INC.

Deadline

July 5 2024

Class Period

3/24/21 - 4/3/24

Allegations

(1) AXT, Inc. overstated its property holdings; (2) the Company did not disclose
that the attempted listing of an AXT, Inc. subsidiary in China had reportedly
failed; (3) AXT, Inc. routinely engaged in environmental violations and unsafe
business practices; (4) AXT, Inc.’s production declined in 2023; and (5) as a
result, defendants’ statements about its business, operations, and prospects
were materially false and misleading and/or lacked a reasonable basis at all
times.

Class Period

3/24/21 - 4/3/24

Deadline

July 5 2024

Learn More

28

Days Left

ALT

ALTIMMUNE, INC.

Deadline

July 5 2024

Class Period

12/1/23 - 4/26/24

Allegations

(i) Altimmune overstated the potential for its lead product candidate,
pemvidutide, to stand out from competing glucagon-like peptide-1 agonists based
on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial;
(ii) accordingly, the MOMENTUM Trial results were less significant to
pemvidutide’s clinical, commercial, and competitive prospects than Defendants
had led investors to believe; (iii) as a result of all the foregoing, defendants
had overstated Altimmune’s prospects for finding a strategic partner to develop
pemvidutide; and (iv) as a result, the Company’s public statements were
materially false and misleading at all relevant times.

Class Period

12/1/23 - 4/26/24

Deadline

July 5 2024

Learn More

32

Days Left

LI

LI AUTO INC.

Deadline

July 9 2024

Class Period

2/26/24 - 5/20/24

Allegations

(i) Li Auto had overstated the demand for its vehicles and the efficacy of its
operating strategy in launching its battery electric minivan, Li MEGA; (ii)
accordingly, the Company was unlikely to meet its Q1 2024 vehicle deliveries
estimate; (iii) the foregoing, once revealed, was likely to have a material
negative impact on the Company’s financial condition; and (iv) as a result, the
Company’s public statements were materially false and misleading at all relevant
times.

Class Period

2/26/24 - 5/20/24

Deadline

July 9 2024

Learn More

35

Days Left

NARI

INARI MEDICAL, INC.

Deadline

July 12 2024

Class Period

2/23/22 - 2/28/24

Allegations

(i) the Company deceived the investing public, including plaintiff; (ii) cause
the market price of Inari common stock to trade above its true value; and (iii)
cause plaintiff as well as other class members to purchase or otherwise acquire
Inari common stock at artificially inflated prices that did not reflect the
stock’s true value during the class period. In furtherance of their unlawful
scheme, plan, or course of conduct, defendants took the actions alleged herein.

Class Period

2/23/22 - 2/28/24

Deadline

July 12 2024

Learn More

35

Days Left

SPT

SPROUT SOCIAL, INC.

Deadline

July 12 2024

Class Period

11/2/23 - 5/2/24

Allegations

(1) the Company’s sales and revenue growth were not indicative of the Company’s
growth as it transitioned to an enterprise sales cycle; (2) the Company faced
integration challenges with its acquisition of Tagger, a leading influencer
marketing and social intelligence platform; (3) as a result, the Company was
“self inducing sales headwinds;” (4) as a result, the Company would revise
fiscal year 2024 revenue guidance; and (5) as a result of the foregoing,
defendants’ positive statements about the Company’s business, operations, and
prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/2/23 - 5/2/24

Deadline

July 12 2024

Learn More

38

Days Left

UNH

UNITEDHEALTH GROUP INC.

Deadline

July 15 2024

Class Period

3/14/22 - 2/27/24

Allegations

According to the filed complaint, defendants made false statements and/or
concealed that: In truth, UnitedHealth never established proper firewalls
between it's complementary businesses, Optum and UnitedHealthcare as required by
its own policy, and as it told the court in the antitrust action, the DOJ and
investors it would do. Firewalls were never properly created for certain
business applications. Despite assurances to the contrary, there was never a
meaningful technological separation between Optum and UnitedHealthcare that
prevented the sharing of customer sensitive information.

Class Period

3/14/22 - 2/27/24

Deadline

July 15 2024

Learn More

39

Days Left

TDOC

TELADOC HEALTH, INC.

Deadline

July 16 2024

Class Period

11/2/22 - 2/20/24

Allegations

According to the complaint, on February 20, 2024, Teladoc announced its fourth
quarter and full year results for the period ended December 31, 2023. The
announcement disclosed that Teladoc had experienced substantially less growth
than previous forecasted. The Company also disclosed that it was expecting
decreased revenue for its BetterHelp segment, an online counseling service.
Analysts attributed this trend to BetterHelp’s market saturation and increased
advertising costs causing a rise the cost of customer acquisitions. Following
the release of the earnings report, TDOC shares fell $4.85/share, or 23.6%,
overnight.

Class Period

11/2/22 - 2/20/24

Deadline

July 16 2024

Learn More

39

Days Left

VSTS

VESTIS CORPORATION

Deadline

July 16 2024

Class Period

10/2/23 - 5/1/24

Allegations

(1) Aramark, a company providing food service and facilities management, had
historically underinvested in the business that became Vestis; (2) Vestis
operated with outdated facilities and an underperforming sales force; (3)
Vestis’s outdated facilities and underperforming sales force led to “service
gaps” that had impeded the Company’s levers of growth and had resulted in
customer attrition; and (4) as a result of the above, defendants’ statements
about Vestis’s business, operations, and prospects were materially false and
misleading and/or lacked a reasonable basis at all relevant times.

Class Period

10/2/23 - 5/1/24

Deadline

July 16 2024

Learn More

45

Days Left

CMBM

CAMBIUM NETWORKS CORPORATION

Deadline

July 22 2024

Class Period

5/8/23 - 1/18/24

Allegations

(1) there was a buildup of inventory in the Company’s distribution channels; (2)
the Company and its distributors were reasonably likely to offer aggressive
discounts to reduce the high channel inventories; (3) the Company’s revenue
would decline sequentially until the excess channel inventory was sold through;
(4) Cambium was likely to incur significant charges to writedown excess and
obsolete inventory; (5) as a result of the foregoing, the Company’s fiscal 2023
revenue and earnings would be adversely affected; and (6) as a result of the
foregoing, defendants’ positive statements about the Company’s business,
operations, and prospects were materially misleading and/or lacked a reasonable
basis.

Class Period

5/8/23 - 1/18/24

Deadline

July 22 2024

Learn More

45

Days Left

BIIB

BIOGEN INC.

Deadline

July 22 2024

Class Period

2/3/22 - 2/13/24

Allegations

(i) Biogen had overstated its efforts to enhance its transparency, corporate
governance, and compliance controls and procedures, as well as the efficacy of
those controls and procedures; (ii) accordingly, Biogen maintained inadequate
compliance controls and procedures in connection with its business operations in
foreign countries; (iii) Biogen and/or its employees were engaged in unlawful or
otherwise improper conduct in several foreign countries; (iv) the foregoing
subjected the Company to a heightened risk of governmental and/or regulatory
scrutiny and enforcement action, as well as significant legal, financial, and
reputational harm; (v) Biogen overstated the strength of its Alzheimer’s disease
related product portfolio, including the its joint efforts and success with
pharmaceutical company, Eisai, in launching and providing access to Leqembi;
(vi) Biogen also downplayed the negative impact that the Reata Acquisition would
have on its FY 2023 non-GAAP diluted EPS; (vii) all the foregoing were likely to
have a significant negative impact on Biogen’s 2023 results; and (viii) as a
result, the Company’s public statements were materially false and misleading at
all relevant times.

Class Period

2/3/22 - 2/13/24

Deadline

July 22 2024

Learn More

46

Days Left

FSLY

FASTLY, INC.

Deadline

July 23 2024

Class Period

2/15/24 - 5/1/24

Allegations

(i) contrary to its representations to investors, Fastly was in fact
experiencing a significant deceleration in growth among its largest customers
and was losing the increased market share it had gained as a result of the 2023
content delivery network consolidation trend; (ii) the foregoing issues were
likely to have a material negative impact on the Company’s revenue growth; (iii)
accordingly, the Company was unlikely to meet its own previously issued revenue
guidance for FY 2024; (iv) as a result, the Company’s financial position and/or
prospects were overstated; and (v) as a result, the Company’s public statements
were materially false and misleading at all relevant times.

Class Period

2/15/24 - 5/1/24

Deadline

July 23 2024

Learn More

52

Days Left

ENPH

ENPHASE ENERGY, INC.

Deadline

July 29 2024

Class Period

2/7/23 - 4/25/23

Allegations

According to the complaint, on April 25, 2023, Enphase issued a press release
announcing its first quarter earnings. In pertinent part, defendants announced
revenue in the United States had decreased by approximately 9% attributing it to
macroeconomic conditions. Additionally, defendants put out a weak second quarter
outlook for 2023 where revenue was estimated to be within the range of $700
million to $750 million. Following this news, the price of Enphase’s common
stock declined dramatically. From a closing market price of $220.60 per share on
April 25, 2023, Enphase’s stock price fell to $163.83 per share on April 26,
2023, a decline of nearly 26% in the span of just a single day.

Class Period

2/7/23 - 4/25/23

Deadline

July 29 2024

Learn More

53

Days Left

RIVN

RIVIAN AUTOMOTIVE, INC.

Deadline

July 30 2024

Class Period

8/12/22 - 2/21/24

Allegations

(i) Rivian had overstated demand for its products, as well as its ability to
withstand negative, near-term macroeconomic impacts; (ii) accordingly, Rivian’s
business was experiencing reduced demand and increased customer cancellations as
a result of, inter alia, high interest rates; (iii) as a result, Rivian’s order
bank had significantly deteriorated; (iv) all the foregoing was likely to, and
did, negatively impact the Company’s anticipated earnings and vehicle production
targets for 2024; and (v) as a result, the Company’s public statements were
materially false and misleading at all relevant times.

Class Period

8/12/22 - 2/21/24

Deadline

July 30 2024

Learn More

53

Days Left

HTZ

HERTZ GLOBAL HOLDINGS, INC.

Deadline

July 30 2024

Class Period

4/27/23 - 4/24/24

Allegations

(i) Hertz had downplayed the financial impact of vehicle depreciation, and/or
overstated its ability to track and manage vehicle depreciation; (ii) demand for
Hertz’s EVs was not as strong as Defendants had led investors to believe; (iii)
Hertz had too many vehicles, particularly EVs, in its fleet to remain
profitable; (iv) as a result of all the foregoing, Hertz was likely to incur
significant losses on the disposition of both its ICE vehicles and EVs; (v) all
the foregoing was likely to, and did, have a significant negative impact on
Hertz’s financial results; and (vi) as a result, the Company’s public statements
were materially false and misleading at all relevant times.

Class Period

4/27/23 - 4/24/24

Deadline

July 30 2024

Learn More

59

Days Left

MRNS

MARINUS PHARMACEUTICALS, INC.

Deadline

August 5 2024

Class Period

3/17/21 - 5/7/24

Allegations

(1) defendants understated the risk of failure to meet the early-stopping
criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2)
defendants did not disclose that a possible consequence of failing to meet the
early stopping criteria in the RAISE trial would be that Marinus would stop the
separate Phase 3 RAISE II trial; and (3) as a result, defendants’ statements
about its business, operations, and prospects, were materially false and
misleading and/or lacked a reasonable basis at all times.

Class Period

3/17/21 - 5/7/24

Deadline

August 5 2024

Learn More

4

Days Left

VFS

VINFAST AUTO LTD. F/K/A BLACK SPADE ACQUISITION CO.

Deadline

June 11 2024

Class Period

8/15/23 - 1/17/24

Allegations

(i) VinFast lacked sufficient capital to execute its purported growth strategy;
(ii) VinFast would be unable to meet its 2023 delivery targets; (iii)
accordingly, VinFast had overstated the strength of its business model and
operational capabilities, as well as its post- merger business and/or financial
prospects; and (iv) as a result, the offering documents and defendants’ public
statements throughout the class period were materially false and/or misleading
and failed to state information required to be stated therein.

Class Period

8/15/23 - 1/17/24

Deadline

June 11 2024

Learn More

4

Days Left

QDEL

QUIDELORTHO CORPORATION F/K/A QUIDEL CORPORATION

Deadline

June 11 2024

Class Period

2/18/22 - 4/1/24

Allegations

(a) that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy
chain customers than they could resell to healthcare providers and end
customers; (b) that excess inventories of COVID-19 tests existed throughout the
supply chain; (c) that, as a result of (a)-(b) above, QuidelOrtho’s distributors
and pharmacy chain customers were poised to significantly reduce their COVID-19
test orders; (d) that undisclosed problems created a heightened risk that the
new test called the savanna respiratory viral panel-4 test would experience a
delayed commercial launch in the united states; (e) that, as a result of (a)-(d)
above, defendants lacked a reasonable basis for their positive statements about
QuidelOrtho’s business, financials, and growth trajectory.

Class Period

2/18/22 - 4/1/24

Deadline

June 11 2024

Learn More

10

Days Left

PERI

PERION NETWORK LTD.

Deadline

June 17 2024

Class Period

2/9/21 - 4/5/24

Allegations

(1) Perion’s search advertising business was not a reliable and significant
growth driver and was in fact in decline; (2) Perion’s long-term relationship
with Microsoft and search services agreement would not provide stability for
Perion’s search advertising business; (3) there was an increased risk of
Microsoft acting to unilaterally change its advertising pricing and mechanisms
to the detriment of Perion while the search services agreement was in place; (4)
Perion’s AI technology and Microsoft’s investment in ChatGPT, a form of
generative AI, would not protect or grow Perion’s search advertising revenue;
and (5) based on the foregoing, defendants lacked a reasonable basis for their
positive statements about Perion’s search advertising business and related
financial results, growth, and prospects.

Class Period

2/9/21 - 4/5/24

Deadline

June 17 2024

Learn More

10

Days Left

ASTS

AST SPACEMOBILE, INC.

Deadline

June 17 2024

Class Period

11/14/23 - 4/1/24

Allegations

(1) production of the Company’s five first generation of commercial satellites,
Block 1 BlueBird satellites, had been negatively impacted by two suppliers of
key subsystems; (2) a result, the Company had not substantially completed the
production of the Block 1 BlueBird satellites; (3) as a result, the Company’s
five Block 1 BlueBird satellites were not on track to launch in the first
quarter of 2024; and (4) as a result of the foregoing, defendants’ positive
statements about the Company’s business, operations, and prospects were
materially misleading and/or lacked a reasonable basis.

Class Period

11/14/23 - 4/1/24

Deadline

June 17 2024

Learn More

11

Days Left

SHCR

SHARECARE, INC.

Deadline

June 18 2024

Class Period

5/10/23 - 3/28/24

Allegations

(1) Sharecare lacked adequate internal controls and; (2) as a result,
defendants’ statements about its business, operations, and prospects, were
materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

5/10/23 - 3/28/24

Deadline

June 18 2024

Learn More

14

Days Left

GDRX

GOODRX HOLDINGS, INC.

Deadline

June 21 2024

Class Period

9/23/22 - 11/8/22

Allegations

(1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx
discounts, Kroger was responsible for nearly 25% of GoodRx’s total prescription
transactions revenue (the Company’s primary revenue stream); and (2) Kroger
could unilaterally cease accepting GoodRx discounts, cutting off some or all of
GoodRx’s revenues for purchases at Kroger’s pharmacies; and (3) as a result,
defendants’ representations about the Company’s business, operations, and
prospects were materially false and misleading and/or lacked a reasonable basis.

Class Period

9/23/22 - 11/8/22

Deadline

June 21 2024

Learn More

17

Days Left

LNC

LINCOLN NATIONAL CORPORATION

Deadline

June 24 2024

Class Period

11/4/20 - 11/2/22

Allegations

(1) the Company was experiencing a decline in its variable universal life
insurance business; (2) as a result, the goodwill associated with the life
insurance business was overstated; (3) as a result, the Company’s policy lapse
assumptions were outdated; (4) as a result, the Company’s reserves were
overstated; (5) as a result, the Company’s reported financial results and
financial statements were misstated; and (6) as a result of the foregoing,
defendants’ positive statements about the Company’s business, operations, and
prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/4/20 - 11/2/22

Deadline

June 24 2024

Learn More

17

Days Left

CMP

COMPASS MINERALS INTERNATIONAL, INC.

Deadline

June 24 2024

Class Period

11/29/23 - 3/22/24

Allegations

(1) Compass Minerals overstated the likelihood that it would be awarded a
renewed U.S. Forest Service contract for the use of its proprietary magnesium
chloride-based aerial fire retardants for the 2024 fire season, as a result of
safety issues presented by its fire retardant; (2) Compass Minerals materially
overstated the extent to which testing had confirmed that its fire retardants
were safe; and (3) as a result, defendants’ statements about its business,
operations, and prospects were materially false and misleading and/or lacked a
reasonable basis at all times.

Class Period

11/29/23 - 3/22/24

Deadline

June 24 2024

Learn More

17

Days Left

ADSK

AUTODESK, INC.

Deadline

June 24 2024

Class Period

6/1/23 - 4/16/24

Allegations

(1) Autodesk, Inc. lacked adequate internal controls as a result of issues with
its free cash flow and non-GAAP operating margin practices; and (2) as a result,
defendants’ statements about its business, operations, and prospects were
materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

6/1/23 - 4/16/24

Deadline

June 24 2024

Learn More

18

Days Left

AKRO

AKERO THERAPEUTICS, INC.

Deadline

June 25 2024

Class Period

9/13/22 - 10/9/23

Allegations

(i) approximately 20% of the patients enrolled in the SYMMETRY study, a trial
that purportedly tested efruxifermin ("EFX") in patients with nonalcoholic
steatohepatitis (“NASH”) -induced cirrhosis, had cryptogenic cirrhosis and did
not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients
included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis
due to definitive NASH; (iii) the results from the cryptogenic cirrhosis
patients were to be excluded from the calculation of the NASH resolution
secondary endpoints; (iv) Akero had introduced a confounding factor into the
SYMMETRY study’s design, materially influencing the study’s potential results
and increasing the risks that the study would fail to meet its primary endpoint;
(v) the SYMMETRY study did not align with U.S. Food & Drug Administration
guidance for testing a drug in treating NASH cirrhotics because Akero had not
rule out potential causes of each patient’s cirrhosis other than NASH; and (vi)
consequently, Akero had materially misrepresented the nature of the SYMMETRY
trial, its usefulness in supporting any new drug application, the likelihood
that the SYMMETRY trial would be successful as measured by its primary endpoint,
and the likelihood that EFX would become a commercial treatment for NASH
cirrhotics.

Class Period

9/13/22 - 10/9/23

Deadline

June 25 2024

Learn More

21

Days Left

MBUU

MALIBU BOATS, INC.

Deadline

June 28 2024

Class Period

11/4/22 - 4/11/24

Allegations

(1) Malibu Boats had engaged in an “elaborate scheme to over manufacture and
pump nearly $100 million of its highest priced, highest margin, slow moving boat
inventory into fifteen Tommy’s dealerships”; (2) as a result, the Company
artificially inflated Malibu’s sales performance, market share, and stock value;
(3) the Company was withholding certain incentives and rebates from its dealers;
(4) as a result of the foregoing, the Company faced substantial risk of
litigation from one of its top dealers, Tommy’s; (5) the Company’s CEO departed
due to his role in this scheme; and (6) as a result of the foregoing,
defendants’ positive statements about the Company’s business, operations, and
prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/4/22 - 4/11/24

Deadline

June 28 2024

Learn More

24

Days Left

GL

GLOBE LIFE INC. F/K/A TORCHMARK CORPORATION

Deadline

July 1 2024

Class Period

5/8/19 - 4/10/24

Allegations

According to the complaint, throughout the Class Period, Globe Life reported
consistent premium revenue growth at the Company, led by consistent premium
revenue growth at American Income Life Insurance Company (“AIL”). The Company
also represented that its employees adhered to a code of conduct that expressly
prohibited various forms of misconduct, and which required that all Globe Life
employees comply with relevant laws and regulations, purportedly ensuring that
the Company would maintain a workplace free from violence, threatening behavior,
and illegal drugs. In truth, Globe Life was engaged in wide-spread insurance
fraud, therefore inflating Globe Life’s financial results. In addition, Globe
Life permitted a culture of unchecked sexual harassment, in direct contravention
of the Company’s Code of Conduct. As a result of defendants’ misrepresentations,
shares of Globe Life common stock traded at artificially inflated prices
throughout the Class Period.

Class Period

5/8/19 - 4/10/24

Deadline

July 1 2024

Learn More

24

Days Left

EQIX

EQUINIX, INC.

Deadline

July 1 2024

Class Period

5/3/19 - 3/24/24

Allegations

(1) Equinix manipulated its financials to reduce operational expenses and boost
Adjusted Funds From Operations (“AFFO”); (2) Equinix oversold power capacity and
did not warn of the risks associated with this practice; (3) Equinix lacked
adequate internal controls; and (4) as a result, defendants’ public statements
were materially false and/or misleading at all relevant times.

Class Period

5/3/19 - 3/24/24

Deadline

July 1 2024

Learn More

25

Days Left

INTC

INTEL CORPORATION

Deadline

July 2 2024

Class Period

1/25/24 - 4/25/24

Allegations

(1) the growth of Intel Foundry Services was not indicative of revenue growth
reportable under the Internal segment; (2) the Foundry experienced significant
operating losses in 2023; (3) the Foundry experienced a decline in product
profit driven by lower internal revenue; (4) as a result the Foundry model would
not be a strong tailwind to the Company’s IFS strategy; and (5) as a result of
the foregoing, defendants’ positive statements about the Company’s business,
operations, and prospects were materially misleading and/or lacked a reasonable
basis.

Class Period

1/25/24 - 4/25/24

Deadline

July 2 2024

Learn More

28

Days Left

AXTI

AXT, INC.

Deadline

July 5 2024

Class Period

3/24/21 - 4/3/24

Allegations

(1) AXT, Inc. overstated its property holdings; (2) the Company did not disclose
that the attempted listing of an AXT, Inc. subsidiary in China had reportedly
failed; (3) AXT, Inc. routinely engaged in environmental violations and unsafe
business practices; (4) AXT, Inc.’s production declined in 2023; and (5) as a
result, defendants’ statements about its business, operations, and prospects
were materially false and misleading and/or lacked a reasonable basis at all
times.

Class Period

3/24/21 - 4/3/24

Deadline

July 5 2024

Learn More

28

Days Left

ALT

ALTIMMUNE, INC.

Deadline

July 5 2024

Class Period

12/1/23 - 4/26/24

Allegations

(i) Altimmune overstated the potential for its lead product candidate,
pemvidutide, to stand out from competing glucagon-like peptide-1 agonists based
on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial;
(ii) accordingly, the MOMENTUM Trial results were less significant to
pemvidutide’s clinical, commercial, and competitive prospects than Defendants
had led investors to believe; (iii) as a result of all the foregoing, defendants
had overstated Altimmune’s prospects for finding a strategic partner to develop
pemvidutide; and (iv) as a result, the Company’s public statements were
materially false and misleading at all relevant times.

Class Period

12/1/23 - 4/26/24

Deadline

July 5 2024

Learn More

32

Days Left

LI

LI AUTO INC.

Deadline

July 9 2024

Class Period

2/26/24 - 5/20/24

Allegations

(i) Li Auto had overstated the demand for its vehicles and the efficacy of its
operating strategy in launching its battery electric minivan, Li MEGA; (ii)
accordingly, the Company was unlikely to meet its Q1 2024 vehicle deliveries
estimate; (iii) the foregoing, once revealed, was likely to have a material
negative impact on the Company’s financial condition; and (iv) as a result, the
Company’s public statements were materially false and misleading at all relevant
times.

Class Period

2/26/24 - 5/20/24

Deadline

July 9 2024

Learn More

35

Days Left

NARI

INARI MEDICAL, INC.

Deadline

July 12 2024

Class Period

2/23/22 - 2/28/24

Allegations

(i) the Company deceived the investing public, including plaintiff; (ii) cause
the market price of Inari common stock to trade above its true value; and (iii)
cause plaintiff as well as other class members to purchase or otherwise acquire
Inari common stock at artificially inflated prices that did not reflect the
stock’s true value during the class period. In furtherance of their unlawful
scheme, plan, or course of conduct, defendants took the actions alleged herein.

Class Period

2/23/22 - 2/28/24

Deadline

July 12 2024

Learn More

35

Days Left

SPT

SPROUT SOCIAL, INC.

Deadline

July 12 2024

Class Period

11/2/23 - 5/2/24

Allegations

(1) the Company’s sales and revenue growth were not indicative of the Company’s
growth as it transitioned to an enterprise sales cycle; (2) the Company faced
integration challenges with its acquisition of Tagger, a leading influencer
marketing and social intelligence platform; (3) as a result, the Company was
“self inducing sales headwinds;” (4) as a result, the Company would revise
fiscal year 2024 revenue guidance; and (5) as a result of the foregoing,
defendants’ positive statements about the Company’s business, operations, and
prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/2/23 - 5/2/24

Deadline

July 12 2024

Learn More

38

Days Left

UNH

UNITEDHEALTH GROUP INC.

Deadline

July 15 2024

Class Period

3/14/22 - 2/27/24

Allegations

According to the filed complaint, defendants made false statements and/or
concealed that: In truth, UnitedHealth never established proper firewalls
between it's complementary businesses, Optum and UnitedHealthcare as required by
its own policy, and as it told the court in the antitrust action, the DOJ and
investors it would do. Firewalls were never properly created for certain
business applications. Despite assurances to the contrary, there was never a
meaningful technological separation between Optum and UnitedHealthcare that
prevented the sharing of customer sensitive information.

Class Period

3/14/22 - 2/27/24

Deadline

July 15 2024

Learn More

39

Days Left

TDOC

TELADOC HEALTH, INC.

Deadline

July 16 2024

Class Period

11/2/22 - 2/20/24

Allegations

According to the complaint, on February 20, 2024, Teladoc announced its fourth
quarter and full year results for the period ended December 31, 2023. The
announcement disclosed that Teladoc had experienced substantially less growth
than previous forecasted. The Company also disclosed that it was expecting
decreased revenue for its BetterHelp segment, an online counseling service.
Analysts attributed this trend to BetterHelp’s market saturation and increased
advertising costs causing a rise the cost of customer acquisitions. Following
the release of the earnings report, TDOC shares fell $4.85/share, or 23.6%,
overnight.

Class Period

11/2/22 - 2/20/24

Deadline

July 16 2024

Learn More

39

Days Left

VSTS

VESTIS CORPORATION

Deadline

July 16 2024

Class Period

10/2/23 - 5/1/24

Allegations

(1) Aramark, a company providing food service and facilities management, had
historically underinvested in the business that became Vestis; (2) Vestis
operated with outdated facilities and an underperforming sales force; (3)
Vestis’s outdated facilities and underperforming sales force led to “service
gaps” that had impeded the Company’s levers of growth and had resulted in
customer attrition; and (4) as a result of the above, defendants’ statements
about Vestis’s business, operations, and prospects were materially false and
misleading and/or lacked a reasonable basis at all relevant times.

Class Period

10/2/23 - 5/1/24

Deadline

July 16 2024

Learn More

45

Days Left

CMBM

CAMBIUM NETWORKS CORPORATION

Deadline

July 22 2024

Class Period

5/8/23 - 1/18/24

Allegations

(1) there was a buildup of inventory in the Company’s distribution channels; (2)
the Company and its distributors were reasonably likely to offer aggressive
discounts to reduce the high channel inventories; (3) the Company’s revenue
would decline sequentially until the excess channel inventory was sold through;
(4) Cambium was likely to incur significant charges to writedown excess and
obsolete inventory; (5) as a result of the foregoing, the Company’s fiscal 2023
revenue and earnings would be adversely affected; and (6) as a result of the
foregoing, defendants’ positive statements about the Company’s business,
operations, and prospects were materially misleading and/or lacked a reasonable
basis.

Class Period

5/8/23 - 1/18/24

Deadline

July 22 2024

Learn More

45

Days Left

BIIB

BIOGEN INC.

Deadline

July 22 2024

Class Period

2/3/22 - 2/13/24

Allegations

(i) Biogen had overstated its efforts to enhance its transparency, corporate
governance, and compliance controls and procedures, as well as the efficacy of
those controls and procedures; (ii) accordingly, Biogen maintained inadequate
compliance controls and procedures in connection with its business operations in
foreign countries; (iii) Biogen and/or its employees were engaged in unlawful or
otherwise improper conduct in several foreign countries; (iv) the foregoing
subjected the Company to a heightened risk of governmental and/or regulatory
scrutiny and enforcement action, as well as significant legal, financial, and
reputational harm; (v) Biogen overstated the strength of its Alzheimer’s disease
related product portfolio, including the its joint efforts and success with
pharmaceutical company, Eisai, in launching and providing access to Leqembi;
(vi) Biogen also downplayed the negative impact that the Reata Acquisition would
have on its FY 2023 non-GAAP diluted EPS; (vii) all the foregoing were likely to
have a significant negative impact on Biogen’s 2023 results; and (viii) as a
result, the Company’s public statements were materially false and misleading at
all relevant times.

Class Period

2/3/22 - 2/13/24

Deadline

July 22 2024

Learn More

46

Days Left

FSLY

FASTLY, INC.

Deadline

July 23 2024

Class Period

2/15/24 - 5/1/24

Allegations

(i) contrary to its representations to investors, Fastly was in fact
experiencing a significant deceleration in growth among its largest customers
and was losing the increased market share it had gained as a result of the 2023
content delivery network consolidation trend; (ii) the foregoing issues were
likely to have a material negative impact on the Company’s revenue growth; (iii)
accordingly, the Company was unlikely to meet its own previously issued revenue
guidance for FY 2024; (iv) as a result, the Company’s financial position and/or
prospects were overstated; and (v) as a result, the Company’s public statements
were materially false and misleading at all relevant times.

Class Period

2/15/24 - 5/1/24

Deadline

July 23 2024

Learn More

52

Days Left

ENPH

ENPHASE ENERGY, INC.

Deadline

July 29 2024

Class Period

2/7/23 - 4/25/23

Allegations

According to the complaint, on April 25, 2023, Enphase issued a press release
announcing its first quarter earnings. In pertinent part, defendants announced
revenue in the United States had decreased by approximately 9% attributing it to
macroeconomic conditions. Additionally, defendants put out a weak second quarter
outlook for 2023 where revenue was estimated to be within the range of $700
million to $750 million. Following this news, the price of Enphase’s common
stock declined dramatically. From a closing market price of $220.60 per share on
April 25, 2023, Enphase’s stock price fell to $163.83 per share on April 26,
2023, a decline of nearly 26% in the span of just a single day.

Class Period

2/7/23 - 4/25/23

Deadline

July 29 2024

Learn More

53

Days Left

RIVN

RIVIAN AUTOMOTIVE, INC.

Deadline

July 30 2024

Class Period

8/12/22 - 2/21/24

Allegations

(i) Rivian had overstated demand for its products, as well as its ability to
withstand negative, near-term macroeconomic impacts; (ii) accordingly, Rivian’s
business was experiencing reduced demand and increased customer cancellations as
a result of, inter alia, high interest rates; (iii) as a result, Rivian’s order
bank had significantly deteriorated; (iv) all the foregoing was likely to, and
did, negatively impact the Company’s anticipated earnings and vehicle production
targets for 2024; and (v) as a result, the Company’s public statements were
materially false and misleading at all relevant times.

Class Period

8/12/22 - 2/21/24

Deadline

July 30 2024

Learn More

53

Days Left

HTZ

HERTZ GLOBAL HOLDINGS, INC.

Deadline

July 30 2024

Class Period

4/27/23 - 4/24/24

Allegations

(i) Hertz had downplayed the financial impact of vehicle depreciation, and/or
overstated its ability to track and manage vehicle depreciation; (ii) demand for
Hertz’s EVs was not as strong as Defendants had led investors to believe; (iii)
Hertz had too many vehicles, particularly EVs, in its fleet to remain
profitable; (iv) as a result of all the foregoing, Hertz was likely to incur
significant losses on the disposition of both its ICE vehicles and EVs; (v) all
the foregoing was likely to, and did, have a significant negative impact on
Hertz’s financial results; and (vi) as a result, the Company’s public statements
were materially false and misleading at all relevant times.

Class Period

4/27/23 - 4/24/24

Deadline

July 30 2024

Learn More

59

Days Left

MRNS

MARINUS PHARMACEUTICALS, INC.

Deadline

August 5 2024

Class Period

3/17/21 - 5/7/24

Allegations

(1) defendants understated the risk of failure to meet the early-stopping
criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2)
defendants did not disclose that a possible consequence of failing to meet the
early stopping criteria in the RAISE trial would be that Marinus would stop the
separate Phase 3 RAISE II trial; and (3) as a result, defendants’ statements
about its business, operations, and prospects, were materially false and
misleading and/or lacked a reasonable basis at all times.

Class Period

3/17/21 - 5/7/24

Deadline

August 5 2024

Learn More

 * 1
 * 2
 * 3
 * 4
 * 5
 * 6
 * 7
 * 8

View All Deadlines


NEWS

Stay informed with the latest in settlement notices, case updates, publications,
analyst reports, and more.
View All News



Learn More

INNOVIZ SHAREHOLDERS WILL BE REPRESENTED BY LEVI & KORSINSKY & POMERANTZ

Lucid Alternative Fund, LP v. Innoviz Technologies Ltd., et al.,
1:24-cv-01971-AT is a lawsuit currently pending in the United States District
Court for the Southern District of New York. The action was filed on behalf of
investors in Innoviz Technologies Ltd. (NASDAQ: INVZ) who allegedly suffered
losses due to securities fraud by the company. On...Read more

June 7, 2024

Learn More

LEVI & KORSINSKY RANKED AMONG THE TOP 50 PLAINTIFFS' FIRMS OF 2023

Levi & Korsinsky (“L&K”) has once again been recognized by Institutional
Shareholder Services Securities Class Action Services (“ISS SCAS”) as one of the
top 50 plaintiffs’ firms in the United States, recovering over $133 million for
investors in securities-related class action settlements in 2023. On April 22,
2024, ISS SCAS released its “Top Plaintiff Law...Read more

May 14, 2024

Learn More

LANTRONIX, INC. LAWSUIT PROCEEDS WITH SELECTION OF CO-LEAD PLAINTIFFS

Neilsen v. Lantronix, Inc., et al., 8:24-cv-00385-FWS-JDE is a lawsuit currently
pending in the United States District Court for the Central District of
California. The action was filed on behalf of investors in Lantronix, Inc.
(NASDAQ: LTRX) who allegedly suffered losses due to securities fraud by the
company. On May 7, 2024, United States District...Read more

May 13, 2024

View All News


OUR WORLD-CLASS TEAM

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal
courts across the country. We have the specialized securities skills to achieve
outstanding results, and our impressive variety of backgrounds means that we can
go up against large companies of any kind and win. Our powerhouse attorneys have
backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory
analysis, international business, and prosecution, to name just a few. . .

View Attorneys


 * Cases
 * Settlements
 * Attorneys
 * Firm
 * L&K Insights
 * News

© 2024 Levi & Korsinsky, LLP

Under the rules of certain jurisdictions, this website may constitute attorney
advertising.

Terms & Conditions

Privacy Notice

 * 
 * 
 * 
 * 

 * Cases
 * Settlements
 * Attorneys
 * Firm
 * L&K Insights
 * News

We use cookies to ensure that we give you the best experience on our website. By
using our website, you agree to the use of cookies.OkPrivacy policy